Xenetic Biosciences
XBIO
10 hedge funds and large institutions have $615K invested in Xenetic Biosciences in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
583% more capital invested
Capital invested by funds: $90.1K → $615K (+$525K)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more funds holding
Funds holding: 8 → 10 (+2)
0.19% more ownership
Funds ownership: 0.16% → 0.35% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$134K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$38.7K |
| 4 |
VF
Virtu Financial
New York
|
+$23.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $347K | +$134K | +11,099 | +187% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $81K | +$48.1K | +3,971 | New |
|
|
TSS
3
Two Sigma Securities
New York
| $65K | +$38.7K | +3,201 | New |
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $55K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $40K | +$23.7K | +1,960 | New |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| $26K | +$16K | +1,318 | New |
|
7
Morgan Stanley
New York
| $1K | – | – | – |
|
|
RE
8
RBC Europe
London,
United Kingdom
| $216 | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$9K | -940 | Closed |
|
|
10
Osaic Holdings
Scottsdale,
Arizona
| – | -$3K | -300 | Closed |
|
XBIO Hedge Fund Activity: Q4 2020 in Review
10 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q4 2020, worth a combined $615K — up 583% from $90.1K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new XBIO positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $134K. The largest seller was UBS Group, exiting entirely with an estimated $9K sold.
- 10 institutional investors held Xenetic Biosciences (XBIO) as of Q4 2020, up from 8 in Q3 2020.
- Funds reported $615K of Xenetic Biosciences stock for Q4 2020, up 583% quarter-over-quarter.
- 4 funds opened new Xenetic Biosciences positions in Q4 2020 and 2 closed out, a net change of +2 holders.
- The largest Xenetic Biosciences buyer in Q4 2020 was Renaissance Technologies, an estimated $134K added.
- The largest Xenetic Biosciences seller in Q4 2020 was UBS Group, an estimated $9K sold.
Based on aggregated 13F filings for Q4 2020.